Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting
Thryv Therapeutics Inc., a biotechnology company pioneering precision treatment to treat indications including Congenital Long QT Syndrome, atrial fibrillation, and heart failure, today announced a poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA. This presentation will take place on Friday, May 17th, from 10:30 a.m. to 12:30 p.m. ET. The meeting will commence with a presentation by Thryv co-founder and Principal Scientific Advisor, Dr. Saumya Das, at the Stanford Biodesign New Arrhythmia Technologies Retreat in Boston, where he will discuss Small Molecules for Arrhythmia Therapy.
Thryv Therapeutics to Participate at the Piper Sandler Spring Biopharma Symposium
Thryv Therapeutics is pleased to announce that it will be hosting investor meetings at the Piper Sandler Spring Biopharma Symposium on Tuesday, April 16, 2024, at the Encore Boston Harbor.
Thryv Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Thryv Therapeutics is pleased to announce its selection as a featured presenter at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The virtual presentation will take place on Tuesday, April 16th, 2024, from 3:00 p.m. to 3:30 p.m. ET.
Thryv Therapeutics to Present Results of Wave I Part 1 Clinical Study at American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024
Thryv Therapeutics is pleased to announce the presentation of its poster: SGK1 inhibitor LQT-1213 significantly attenuates dofetilide-induced QT prolongation in humans: Results of the WAVE I Clinical Study at the American College of Cardiology Conference. Thryv’s poster presentation will be presented on Sunday, April 7th from 12:15 p.m. - 1:00 p.m. in Hall B4-5.
Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Evercore ISI 2024 Emerging Biotech Conference that is taking place virtually on February 28th and 29th, 2024. Thryv’s virtual presentation will be on February 28th from 2:15-2:45 p.m. ET.
2023 Year End Report
Reflecting on an incredible year! Our 2023 Year End Report highlights Thryv's milestones in Long QT Syndrome, atrial fibrillation, heart failure, and oncology. From clinical studies to publications and presentations, it's been an exciting year! Huge thanks to our dedicated team, collaborators, and the Thryv community for making it all possible. Here's to an even brighter 2024!
Thryv Therapeutics to Present at the 2023 RBC Capital Markets Private Company Conference
Thryv Therapeutics is pleased to announce its selection as a featured presenter at the 2023 RBC Capital Markets Private Company Conference. The virtual presentation will take place on Thursday, December 14th, 2023, from 10:40 a.m. to 11:10 a.m. ET.
Thryv Therapeutics’ CEO, Paul Truex, to Present at Piper Sandler’s 35th Annual Healthcare Conference
Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Piper Sandler 35th Annual Healthcare Conference, held from November 28th to November 30th, 2023, at Lotte New York Palace in New York City. Paul Truex, Thryv’s Chairman of the Board & Chief Executive Officer, will present on November 29th from 3:50 to 4:10 PM in Harlem Track | Kennedy 2, 4th floor.
Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions
Thryv Therapeutics Inc. is pleased to announce an oral presentation of the effects of SGK-1 inhibition with its’ potent and selective inhibitor THRV-1268 on atrial fibrillation in an obese-mouse model. This abstract will be presented during the Shocking Results: Basic Science Insights into Arrhythmias session at the American Heart Association Annual Scientific Sessions in Philadelphia, PA.
Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT Induced by Dofetilide.
Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in individuals with dofetilide-induced long QT. LQT-1213 is a potent and selective inhibitor of Serum Glucocorticoid inducible Kinase 1 (SGK-1), which is implicated in QTc prolongation.
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
“We are excited to advance our portfolio of potent SGK1 inhibitors into the treatment of aggressive, treatment resistant cancers. SGK1 has been implicated in a number of treatment-resistance oncology pathways and our work has demonstrated the potential to delay resistance and restore activity of approved therapies and ultimately improve progression free and overall survival outcomes,” said Debra Odink, President, and Chief Development Officer.
Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec
While we await results from our initial proof of efficacy study this summer in Long QT Syndrome, we are able to accelerate a number of pipeline initiatives thanks to this new investment from IQ.
Thryv Therapeutics Inc. Announces Completion of Initial Phase 1 Clinical Study and Beginning of Proof of Efficacy Study in Long QT Syndrome
Data from this study demonstrated escalating doses of LQT-1213 up to seven days were well tolerated with good oral bioavailability, favorable pharmacokinetics profile, and no significant adverse events
Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., Appointed to Thryv’s Board of Directors
Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers.
34th Piper Sandler Annual Healthcare Conference and RBC Capital Markets Healthcare Private Company Virtual Conference
Two fireside chats by Mr. Paul F. Truex CEO on Thryv’s progress with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.
Scientific Data for Thryv’s Novel SGK1 inhibitors Presented at American Heart Association and San Antonio Breast Cancer Symposium
Results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation to be presented at the AHA Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago
Dr. Debra Odink appointed to President and Dr. Shi Yin Foo joins our Board of Directors
We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.
Expanding Pipeline Leads to Name Change - LQT Therapeutics Now Thryv Therapeutics
We are excited to announce the evolution of our portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics, embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and stakeholders.
Douglas Wight Appointed as Vice President - Drug Development
Patient identification and enrollment for our pivotal LQTS clinical trial is a strategic focus of LQTT. Mr Wight’s expertise will play a critical role in guiding our clinical and regulatory strategies.
LQTT Collaboration with Leading Cancer Researcher
Dr. Donald McDonnell of Duke University School of Medicine will evaluate LQTT SGK1 inhibitors as potential treatment for people with resistant prostate and breast cancer.